Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

The SOPHIA phase III RCT demonstrated improved progression free survival (n=536; 5.8 vs 4.9 months; HR 0.76; 95% CI, 0.59-0.98; P = 0.03) and improved overall survival (21.6 vs 19.8 months; 0.89; 0.69-1.13; P = 0.33) with margetuximab + chemotherapy vs trastuzumab + chemotherapy.

JAMA Oncology